Clinical trials: Epithelial Neoplasms, Malignant
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Advanced Solid Tumors
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually…
- Trial name
- NCT01999972
- Testing
- axitinib, crizotinib
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with Merkel cell cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma
- Trial name
- NCT03304639
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy
- Where
- 254 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Primary Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
The primary objective of this trial is to compare the rate of pathologically complete remissions achieved using a preoperative dose-intensified 8 week therapy consisting of adriamycin and docetaxel with a preoperative sequential…
- Trial name
- NCT00793377
- Testing
- Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
- Where
- Germany
- Volunteers
- 913 people
- Sponsor
- GBG Forschungs GmbH
Basal Cell Carcinoma, Optical Coherence Tomography
Optical-Coherence Tomography for the Non-invasive Diagnosis and Subtyping of Basal Cell Carcinoma
Rationale: To date, the diagnosis and subtyping of basal cell carcinoma (BCC) is verified with histopathology which requires a biopsy.
- Conditions
- Basal Cell Carcinoma, Optical Coherence Tomography, Deep Learning, Artificial Intelligence
- Trial name
- OCT-BCC (NCT05041777)
- Testing
- Optical Coherence Tomography
- Where
- Netherlands
- Volunteers
- 963 people
- Sponsor
- Maastricht University Medical Center
Lung Neoplasms, Quality of Life
Impact on Quality of Life From Multi-modality Lung Cancer
The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2.
- Trial name
- PIONEER (NCT04540757)
- Testing
- Surgery, No surgery
- Where
- 2 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- The Christie NHS Foundation Trust
Oropharyngeal Cancer
Usefulness of Integrated PET/MRI in Oropharyngeal Squamous Cell Carcinoma Evaluation
Head and neck cancer (HNC) continues to be a significant health care problem in Taiwan and oropharyngeal squamous cell carcinoma (SCC) is the common subtype.
- Trial name
- NCT05299957
- Testing
- PETMRI
- Where
- Taiwan
- Volunteers
- 233 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival…
- Trial name
- NADIM-ADJUVANT (NCT04564157)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- 30 sites in Spain
- Volunteers
- 210 people
- Sponsor
- Fundación GECP
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Collection of Blood Samples in Patients With Non-small Cell Lung Cancer
This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03492801
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Adrenocortical Carcinoma
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of the effect of the included drugs.
- Trial name
- NCT00324012
- Testing
- cisplatin, taxotere
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioma
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
- Trial name
- NCT00526812
- Testing
- RTA 744, RTA 744 injection
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Biogen
Carcinoma, Non-Small-Cell Lung
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). The investigators have finished the preclinical,phase I and phase II clinical studies and found its…
- Trial name
- ANSWER (NCT02332512)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 417 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diffuse Midline Glioma (DMG), Glioblastoma
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other…
- Conditions
- Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
- Trial name
- PNOC023 (NCT04732065)
- Testing
- ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
- Where
- 7 sites in United States, Netherlands and 1 more
- Volunteers
- 208 people
- Sponsor
- Sabine Mueller, MD, PhD
Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
Background: Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer. It most often occurs in young people who have no history of liver disease. Unresectable FLC most often does not improve with surgery.
- Trial name
- NCT04025567
- Testing
- vancomycin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Undifferentiated Carcinoma
- Trial name
- NCT01992861
- Testing
- Computed Tomography, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 51 people
- Sponsor
- University of Washington
High-Grade Glioma
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA…
- Trial name
- NCT06829173
- Testing
- XRD-0394, Radiation Therapy, Surgical Resection
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- NYU Langone Health
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Hepatocellular
Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma
The objective of this study is to study the safety and tumor response of ACE for large HCC.
- Trial name
- NCT03662841
- Testing
- Ablative chemoembolization (ACE)
- Where
- Hong Kong
- Volunteers
- 11 people
- Sponsor
- Chinese University of Hong Kong
Non-small Cell Lung Cancer
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
The purpose of this Phase I study is to test the safety of combining afatinib with standard chemotherapy and radiation. The drug afatinib will be given before the chemotherapy and radiation therapy to shrink the tumor and…
- Trial name
- NCT01836341
- Testing
- Afatinib, Cisplatin, Carboplatin
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer
- Trial name
- NCT00436254
- Testing
- pNGVL3-hICD vaccine, sargramostim, flow cytometry
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.